Zymosan A-Induced Graves Ophthalmopathy Animal Model
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a suitable animal model for researching Graves' ophthalmopathy, a disease with autoimmune mechanisms, limiting the development of effective treatment options due to the difficulty in obtaining human orbital tissues beyond the acute phase of the disease.
Innovation Solution
Administering zymosan A to non-human subjects, such as SKG mice, to induce a phenotype resembling Graves' ophthalmopathy, including blepharitis and exophthalmos, which serves as a model for screening potential therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgenic animal models using genetic recombination are used to study Graves' ophthalmopathy, then the model can represent the disease phenotype, but the model construction is complex and time-consuming
Solution Approach 1:
The patent changes the approach from genetic modification to chemical induction by administering zymosan A to SKG mice. This parameter change from genetic to chemical method achieves the same disease phenotype representation without the complexity of transgenic construction, resolving the contradiction between model reliability and construction complexity
2Quantity of substance
If human orbital tissues are obtained from acute phase patients for research, then the tissue samples can be studied, but the availability is limited and the research scope is constrained
Solution Approach 1:
The patent creates an animal model that copies the human disease phenotype rather than relying on limited human tissue samples. By inducing Graves' ophthalmopathy in SKG mice through zymosan A administration, the model provides abundant orbital tissue that replicates human disease characteristics, thereby expanding research availability and versatility
3Productivity
If no suitable animal model is available for Graves' ophthalmopathy research, then therapeutic agent development is limited, but developing a new model requires extensive validation and time
Solution Approach 1:
The patent performs preliminary validation by demonstrating that zymosan A administration to SKG mice produces consistent Graves' ophthalmopathy phenotypes including exophthalmos, orbital tissue inflammation, and extraocular muscle enlargement. This preliminary characterization establishes the model's suitability for therapeutic screening, enabling productive research while minimizing validation time
Data Source
AI summary
The present disclosure relates to a method for preparing a Graves' ophthalmopathy phenotype animal model, the method including a step of administering zymosan A to a subject other than humans, a Graves' ophthalmopathy phenotype animal model prepared thereby, and a method for screening a therapeutic material for alleviation or treatment of Graves' ophthalmopathy. By using the method for preparing a Graves' ophthalmopathy phenotype animal model, which includes a step of administering zymosan A to a subject other than humans according to the present disclosure, an experimental animal model for Graves' ophthalmopathy, which simultaneously exhibits blepharitis, orbital tissue inflammation, and exophthalmos, may be obtained. In addition, the animal model prepared by the preparation method of the present disclosure may be advantageously used for researching the development of a therapeutic agent for Graves' ophthalmopathy the etiology of which has not been yet accurately revealed.